Literature DB >> 11843854

Mammographic appearance of ductal carcinoma in situ does not reliably predict histologic subtype.

P J Slanetz1, A A Giardino, T Oyama, F C Koerner, E F Halpern, R H Moore, D B Kopans.   

Abstract

Histologic subtypes of ductal carcinoma in situ (DCIS) have been correlated with disease prognosis. There are conflicting reports on whether the grade of DCIS can be predicted by the morphology of calcifications seen on mammography. We undertook this study to determine whether the grade of DCIS can be reliably and accurately determined by mammography prior to excisional biopsy. Ninety consecutive cases of DCIS from 1993 to 1996 were identified, of which 75 cases had mammograms available for review. Any lesion with invasion was excluded. The mammogram showed only a mass in 10 of 75 cases, a mass and calcifications in 3 of 75 cases, and calcifications alone in 62 of 75 cases. Three board-certified radiologists with special expertise in mammography reviewed and categorized the mammographic findings as well, intermediate or poorly differentiated DCIS without knowledge of the histologic diagnosis. Histologic grading was performed without knowledge of the mammographic finding. Receiver operating curves (ROCs) were computed for each of the radiologists. For microcalcifications, the ROC comparisons of the radiologists' opinions of tumor grade and random chance were not significantly different. In those cases with available magnification views, the grade assessment did not change significantly. If only a mass was present on mammography, well-differentiated DCIS was the predominant histologic subtype. A histologic grade of DCIS cannot accurately be determined prospectively based on the mammographic appearance of microcalcifications. However, if only a mass is present, this is more likely to represent well-differentiated DCIS.

Entities:  

Mesh:

Year:  2001        PMID: 11843854     DOI: 10.1046/j.1524-4741.2001.07607.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  7 in total

1.  Characterizing the clustered microcalcifications on mammograms to predict the pathological classification and grading: a mathematical modeling approach.

Authors:  Yuan-Zhi Shao; Li-Zhi Liu; Meng-Jie Bie; Chan-chan Li; Yao-pan Wu; Xiao-ming Xie; Li Li
Journal:  J Digit Imaging       Date:  2011-10       Impact factor: 4.056

2.  Predictive factors for breast cancer in patients diagnosed atypical ductal hyperplasia at core needle biopsy.

Authors:  Byung Joo Chae; Ahwon Lee; Byung Joo Song; Sang Seol Jung
Journal:  World J Surg Oncol       Date:  2009-10-23       Impact factor: 2.754

3.  Independent predictors of breast malignancy in screen-detected microcalcifications: biopsy results in 2545 cases.

Authors:  G Farshid; T Sullivan; P Downey; P G Gill; S Pieterse
Journal:  Br J Cancer       Date:  2011-11-03       Impact factor: 7.640

4.  Screen-detected ductal carcinoma in situ found on stereotactic vacuum-assisted biopsy of suspicious microcalcifications without mass: radiological-histological correlation.

Authors:  Bartlomiej Szynglarewicz; Piotr Kasprzak; Przemyslaw Biecek; Agnieszka Halon; Rafal Matkowski
Journal:  Radiol Oncol       Date:  2016-04-23       Impact factor: 2.991

5.  A Micro CT Study in Patients with Breast Microcalcifications Using a Mathematical Algorithm to Assess 3D Structure.

Authors:  David Kenkel; Zsuzsanna Varga; Heike Heuer; Konstantin J Dedes; Nicole Berger; Lukas Filli; Andreas Boss
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

6.  The ratio of atypical ductal hyperplasia foci to core numbers in needle biopsy: a practical index predicting breast cancer in subsequent excision.

Authors:  Jeong-Ju Lee; Hee Jin Lee; Jun Kang; Jeong-Hyeon Jo; Gyungyub Gong
Journal:  Korean J Pathol       Date:  2012-02-23

7.  Correlation between imaging and pathology in ductal carcinoma in situ of the breast.

Authors:  Marnix A J De Roos; Ruud M Pijnappel; Wendy J Post; Jaap De Vries; Peter C Baas; Lex D Groote
Journal:  World J Surg Oncol       Date:  2004-03-12       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.